1. Signaling Pathways
  2. Cytoskeleton
  3. Myosin

Myosin

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Isoform Specific Products:

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-109037S4
    Mavacamten-d7
    Modulator 99.68%
    Mavacamten-d7 (MYK461-d7) is deuterium labeled Mavacamten. Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d<sub>7</sub>
  • HY-14233S
    Omecamtiv mecarbil-d8
    Activator 99.57%
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d<sub>8</sub>
  • HY-148516A
    (R)-MPH-220
    Inhibitor 99.09%
    (R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness.
    (R)-MPH-220
  • HY-109037R
    Mavacamten (Standard)
    Modulator
    Mavacamten (Standard) is the analytical standard of Mavacamten. This product is intended for research and analytical applications. Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten (Standard)
  • HY-100948B
    ATM-3507 trihydrochloride
    Inhibitor
    ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
    ATM-3507 trihydrochloride
  • HY-152205
    JB061
    Inhibitor 99.27%
    JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM.
    JB061
  • HY-P990614
    LK-1
    Inhibitor 98.73%
    LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    LK-1
  • HY-109128S2
    Danicamtiv-d3-1
    Danicamtiv-d3-1 (MYK-491-d3-1) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
    Danicamtiv-d<sub>3</sub>-1
  • HY-108440
    Shz-1
    99.88%
    Shz-1, a small cardiogenic molecule, induces various cardiac-specific genes including sarcomeric tropomyosin in P19CL6 cells. Shz-1 induces Nkx2.5 expression in mouse. Shz-1 activates the axolotl TPM4 promoter-driven ectopic expression in C2C12 cells.
    Shz-1
  • HY-139622
    DN-F01
    Inhibitor
    DN-F01 has a strong inhibitory calcium-dependent effect on cardiac myofibrillar ATPase activity with an IC50 value of 11 ± 4 nmol/L.
    DN-F01
  • HY-122200R
    Phenamacril (Standard)
    Inhibitor
    Phenamacril (Standard) is the analytical standard of Phenamacril. This product is intended for research and analytical applications. Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species.
    Phenamacril (Standard)
  • HY-P3965A
    16-38-Thymosin β4 (cattle) TFA
    Activator 98.14%
    16-38-Thymosin β4 (cattle) TFA is a Ca2+-independent MLCK activator with high affinity.
    16-38-Thymosin β4 (cattle) TFA
  • HY-163120
    Myosin-IN-1
    Inhibitor 98.14%
    Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research.
    Myosin-IN-1
  • HY-129452
    (S)-3'-Hydroxy blebbistatin
    Inhibitor
    (S)-3'-Hydroxy blebbistatin is a myosin II inhibitor and is more water-soluble than Blebbistatin.
    (S)-3'-Hydroxy blebbistatin
  • HY-100932A
    ML-9 Free Base
    Inhibitor
    ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
    ML-9 Free Base
  • HY-120997
    E6 Berbamine
    Inhibitor
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia.
    E6 Berbamine
  • HY-Y0073R
    4-Hydroxyacetophenone (Standard)
    Activator
    4-Hydroxyacetophenone (Standard) is the analytical standard of 4-Hydroxyacetophenone. This product is intended for research and analytical applications. 4-Hydroxyacetophenone (P-hydroxyacetophenone) is a major hepatoprotective and choleretic compound found in Artemisia and Illicium plants, exhibiting antiviral and anti-inflammatory effects against hepatitis B virus. Additionally, 4-Hydroxyacetophenone inhibits cancer cell adhesion, invasion, and migration by remodeling actin. 4-Hydroxyacetophenone holds promise for research in the fields of inflammatory diseases and cancer.
    4-Hydroxyacetophenone (Standard)
  • HY-152206
    JB062
    Inhibitor
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB062
  • HY-109128S
    Danicamtiv-d6
    Danicamtiv-d6 (MYK-491-d6) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
    Danicamtiv-d<sub>6</sub>
  • HY-P10346
    smMLCK peptide
    Inhibitor
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction.
    smMLCK peptide
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.